Anti-Human IgM (μ-chain specific) antibody produced in goat

affinity isolated antibody, buffered aqueous solution

MDL number:
Pricing and availability is not currently available.

biological source


antibody form

affinity isolated antibody

antibody product type

secondary antibodies




buffered aqueous solution


indirect ELISA: 1:20,000-1:40,000



shipped in

dry ice

storage temp.


Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

IgM antibodies are present as pentamers in the serum and are produced in response to antigens.


Anti-Human IgM (μ-chain specific) antibody produced in goat has been used in enzyme linked immunosorbent assay (ELISA).

Biochem/physiol Actions

Immunoglobulin M (IgM) antibodies are the primary ones to be produced in response to antigen. They bind with low affinity but exhibit a broad specificity to a variety of antigens. IgM constitutes 15% of adult immunoglobulins. IgM is important for fetal and neonatal host defenses for several reasons. IgM molecule efficiently activates classical pathway of complement. Its pentameric structure helps in accomodating multivalent ligand binding. IgM has a prominent role in clearance of invading microorganisms from serum.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide


Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves


NONH for all modes of transport

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

J Ollila et al.
Genes and immunity, 4(5), 343-350 (2003-07-09)
The development of adaptive immunity and responses to foreign molecules and organisms relies on the highly regulated production of hundreds of proteins. B-cell maturation, from committed progenitors to terminally differentiated plasma cells, is a multistep process that requires the ordered...
X Guo et al.
Oncogene, 36(29), 4224-4232 (2017-04-04)
Diffuse large B-cell lymphoma (DLBCL) has been categorized into two molecular subtypes that have prognostic significance, namely germinal center B-cell like (GCB) and activated B-cell like (ABC). Although ABC-DLBCL has been associated with NF-κB activation, the relationships between activation of...
Juha Ollila et al.
Molecular immunology, 44(14), 3537-3551 (2007-05-09)
B-cell development into antibody producing cells is a complex process that relies on the tightly controlled production of hundreds of genes and proteins. A B-cell is activated through the B-cell receptor (BCR) and this activation is modified by different co-stimulatory...
Avery's Diseases of the Newborn E-Book, 460-460 (2011)
Johanna Salonen et al.
PloS one, 8(10), e77894-e77894 (2013-11-10)
B cells play a pivotal role in adaptive immune system, since they maintain a delicate balance between recognition and clearance of foreign pathogens and tolerance to self. During maturation, B cells progress through a series of developmental stages defined by...
Antibody-based serology tests are useful in identifying subjects with an adaptive immune response to the SARS-CoV-2 virus. Anti-human immunoglobulin antibodies allow for quick and simple, yet reliable assays with easy readouts and can also be adapted for high-throughput screening.
Read More

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.